Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin
Autore:
Laurie, SA; Pfister, DG; Kris, MG; Tong, WP; Chronowski, G; Pisters, KWM; Heelan, RT; Sirotnak, FM;
Indirizzi:
Cornell Univ, Weill Med Coll, Mem Sloan Kettering Canc Ctr, Div Solid Tumor Oncol,Dept Med, New York, NY 10021 USA Cornell Univ New York NY USA 10021 Oncol,Dept Med, New York, NY 10021 USA Cornell Univ, Weill Med Coll, Mem Sloan Kettering Canc Ctr, Pharmacol & Therapeut Program, New York, NY 10021 USA Cornell Univ New York NY USA 10021rapeut Program, New York, NY 10021 USA Cornell Univ, Weill Med Coll, Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA Cornell Univ New York NY USA 10021 r, Dept Radiol, New York, NY 10021 USA
Titolo Testata:
CLINICAL CANCER RESEARCH
fascicolo: 3, volume: 7, anno: 2001,
pagine: 501 - 509
SICI:
1078-0432(200103)7:3<501:PIAPSO>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
CELL LUNG-CANCER; METASTATIC BREAST-CANCER; CLINICAL-TRIALS GROUP; ADVANCED SOLID TUMORS; SOFT-TISSUE SARCOMA; DEPENDENT SYNERGISM; LEUCOVORIN RESCUE; CIS-PLATINUM; CHEMOTHERAPY; 10-ETHYL-10-DEAZAAMINOPTERIN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Pfister, DG Cornell Univ, Weill Med Coll, Mem Sloan Kettering Canc Ctr, Div Solid Tumor Oncol,Dept Med, 1275 York Ave, New York, NY 10021 USA CornellUniv 1275 York Ave New York NY USA 10021 NY 10021 USA
Citazione:
S.A. Laurie et al., "Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin", CLIN CANC R, 7(3), 2001, pp. 501-509

Abstract

The antifolate edatrexate has shown moderate activity against cancers of the head and neck and non-small cell lung cancer, as has cisplatin, Edatrexate demonstrates synergy with cisplatin in transplanted tumor models. This Phase I study was designed to evaluate two schedules of administration of cisplatin in combination with escalating doses of edatrexate, in a populationconsisting mainly of patients with these two cancers. The starting dose ofedatrexate was 40 mg/m(2). Dose escalation was to occur in 10-mg/m(2) increments; the planned maximum dose level for study was 80 mg/m(2). A total of39 patients were registered. Eleven were treated on schedule A: cisplatin 120 mg/m(2) every 4 weeks, and edatrexate weekly. Twenty-eight patients were assigned to schedule B: cisplatin 60 mg/m(2) and edatrexate, both given every 2 weeks. On schedule A, the maximum tolerated dose of weekly edatrexate was 40 mg/m(2), with dose-limiting toxicities of leukopenia, mucositis, and renal insufficiency, On schedule B, the maximum tolerated dose of biweekly edatrexate was 80 mg/m(2), with leukopenia and mucositis as dose limiting. For schedule A, pharmacokinetic studies suggested a possible effect of cisplatin on the day 8 clearance of edatrexate, Studies on patients on schedule B did not show a clear effect of cisplatin on the day 15 edatrexate clearance. On schedule A, 5 of 9 evaluable patients had major responses (1 complete); whereas on schedule B, 8 of 25 patients had major responses (1 complete). Responses were seen in both head and neck and non-small cell lung cancer patients, For Phase II studies, use of cisplatin 60 mg/m(2) and edatrexate 80 mg/m(2), both given biweekly, is recommended.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 01:58:22